Mastodon

Bon-Dijon (Powder) Instructions for Use

Marketing Authorization Holder

Moscow Pharmaceutical Factory CJS (Russia)

ATC Code

B05CB04 (Sodium bicarbonate)

Active Substance

Sodium bicarbonate (BP British Pharmacopoeia)

Dosage Form

Bottle OTC Icon Bon-Dijon Powder for preparation of oral solution and topical application 10 g: pkg. 10 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for oral administration and topical application white, crystalline, odorless, with a salty-alkaline taste; aqueous solutions have an alkaline reaction.

1 sachet
Sodium bicarbonate 10 g

10 g – sachets (3) – cardboard packs.
10 g – sachets (5) – cardboard packs.
10 g – sachets (10) – cardboard packs.

Clinical-Pharmacological Group

Acidosis correction preparation for parenteral use

Pharmacotherapeutic Group

Antacid agent

Pharmacological Action

Antacid agent, regulates acid-base balance. It has alkaline properties, increases the alkaline reserve of the blood. When taken orally, it quickly neutralizes hydrochloric acid of gastric juice and has a rapid but short-lived antacid effect.

It irritates the receptors of the gastric mucosa, increases the release of gastrin with secondary activation of secretion, and may cause discomfort in the stomach (due to its distension) and belching.

It has an expectorant effect by reducing the viscosity of sputum due to a shift towards the alkaline side of the reaction of bronchial mucus.

When absorbed, it leads to the development of alkalosis. Alkalinization of urine prevents the precipitation of uric acid in the urinary tract.

It alleviates the symptoms of seasickness and airsickness.

Indications

Metabolic acidosis (including in diabetes mellitus, infections, intoxications, kidney diseases, anesthesia, in the postoperative period); as a symptomatic agent for the relief of heartburn, discomfort in the epigastrium associated with increased acidity of gastric juice; symptomatic treatment of cough with viscous and difficult-to-expectorate sputum in various respiratory tract diseases; seasickness and airsickness.

For topical application: inflammatory diseases of the oral cavity, eyes, upper respiratory tract, for softening earwax.

ICD codes

ICD-10 code Indication
E87.2 Acidosis
H01.0 Blepharitis
H10 Conjunctivitis
H15 Diseases of sclera
H16 Keratitis
H61.2 Impacted cerumen
J00 Acute nasopharyngitis (common cold)
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J06.9 Acute upper respiratory infection, unspecified
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31.0 Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis)
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
K04 Diseases of pulp and periapical tissues (including periodontitis)
K05 Gingivitis and periodontal diseases
K12 Stomatitis and related lesions
K29 Gastritis and duodenitis
R05 Cough
R09.3 Sputum
R10.1 Pain localized to the upper abdomen
R12 Heartburn
T75.3 Motion sickness
ICD-11 code Indication
5C73.Z Acidosis, unspecified
9A01.3 Infectious blepharitis
9A02.Z Inflammatory disorders of eyelid, unspecified
9A60.Z Conjunctivitis, unspecified
9A71 Infectious keratitis
9A7Z Diseases of the cornea, unspecified
9B5Z Disorders of sclera, unspecified
AA42 Impacted cerumen
CA00 Acute nasopharyngitis
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA07.0 Acute upper respiratory tract infection of unspecified site
CA09.0 Chronic rhinitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
DA01.Z Diseases of the oral mucosa, unspecified
DA09.Z Diseases of pulp and periapical tissues, unspecified
DA0B.Z Gingival diseases, unspecified
DA0C.Z Periodontal diseases, unspecified
DA0Z Diseases or disorders of the orofacial complex, unspecified
DA42.Z Gastritis, unspecified
DA51.Z Duodenitis, unspecified
DA7Z Diseases of stomach or duodenum, unspecified
MD10 Abnormal sputum
MD12 Cough
MD81.10 Pain localized in the upper abdomen
MD95 Heartburn
NF08.3 Motion sickness

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

For oral administration, dissolve the contents of one sachet (10 g) in half a glass (100 ml) of cool or warm water. Use the prepared solution immediately.

For heartburn and epigastric discomfort, take the solution orally. The single dose is one sachet. Do not use this regimen systematically or for more than a few days without medical supervision.

As an expectorant for cough with viscous sputum, take the solution orally 2-3 times daily. The duration of use is determined by the physician based on clinical need.

For metabolic acidosis, the dosage is individually calculated by a physician based on the severity of acidosis and blood gas parameters. Do not self-treat this condition.

For motion sickness (seasickness, airsickness), take the solution at the first signs of nausea, following the single dose instructions.

For topical application as a mouthwash or gargle for inflammatory diseases of the oral cavity and pharynx, use a 2% solution (dissolve 2 g of powder in 100 ml of water). Rinse 3-4 times daily.

For eye washes in cases of conjunctivitis or other inflammatory conditions, use a 0.5-2% solution. Apply externally only; ensure the solution is sterile.

To soften earwax, instill a few drops of a warm 1-2% solution into the external auditory canal. Do not use if eardrum perforation is suspected.

Adhere strictly to the recommended concentrations and frequencies of use. Consult a physician for treatment beyond a few days or if symptoms persist.

Adverse Reactions

With prolonged use, the development of alkalosis (sometimes uncompensated) is possible, accompanied by loss of appetite, nausea, vomiting, pain in the epigastric region, anxiety, headaches, and in some severe cases, tetanic convulsions; increased blood pressure, flatulence (when taken orally).

Contraindications

Conditions accompanied by the development of metabolic alkalosis, hypernatremia, hypokalemia.

Use in Pregnancy and Lactation

Should be used with caution during pregnancy and breastfeeding.

Use in Renal Impairment

In patients with concomitant kidney diseases, excessive sodium intake causes edema and heart failure.

Special Precautions

It is not recommended for systematic use because when neutralizing hydrochloric acid of the stomach with sodium bicarbonate, carbon dioxide is released, which has an excitatory effect on the receptors of the gastric mucosa, increases the release of gastrin, and may cause a secondary increase in secretion.

Furthermore, with prolonged regular use, alkalinization of urine and an increased risk of phosphate stone formation are possible.

Intensive release of CO2 may provoke perforation of the gastrointestinal tract walls.

In patients with concomitant heart or kidney diseases, excessive sodium intake causes edema and heart failure.

Drug Interactions

With simultaneous use, the excretion of amphetamine in the urine decreases due to an increase in urine pH under the influence of sodium bicarbonate.

When sodium bicarbonate is taken orally against the background of lithium carbonate use in established maintenance doses, a decrease in lithium concentration in blood plasma is possible, which is due to the influence of sodium ions.

With simultaneous use with methotrexate, the excretion of methotrexate in the urine increases and its toxic effect on the kidneys decreases due to an increase in urine pH under the influence of sodium bicarbonate.

With simultaneous oral administration, the absorption of tetracyclines decreases.

Due to an increase in urine pH under the influence of sodium bicarbonate, a delay in the excretion of ephedrine from the body is observed and the risk of side effects increases (tremor, anxiety, sleep disorders, tachycardia).

With intravenous drip administration of sodium bicarbonate, an enhancement of the antihypertensive effect of reserpine is possible.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS